Cantor Fitzgerald assumed coverage of Aclaris Therapeutics (ACRS) with an Overweight rating.Cantor is bullish on the TSLP and IL-4R bispecific, which looks differentiated, and even early proof-of ...

Cantor Fitzgerald upgraded Tesla (TSLA, Financials) to Overweight from Neutral, citing a buying opportunity following the recent sell-off, the firm announced after a site visit to Tesla's ...

Since ending in correction territory last week, Wall Street has rebounded, and Cantor Fitzgerald believes this rally could extend through to the end of the month. However, despite the potential ...

The Irish unit of Cantor Fitzgerald, the US investment group previously run by Donald Trump’s new commerce secretary, has been fined €452,790 by the Central Bank for failing on a number of ...

Belite Bio, Inc (NASDAQ:BLTE – Free Report) – Research analysts at Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of Belite Bio in a research note issued on Tuesday ...

Friday - Summit Therapeutics plc (NASDAQ:SMMT) stock received a new Overweight rating from Cantor Fitzgerald, signaling a positive outlook from the firm. The coverage initiation by Cantor ...

Protara Therapeutics, Inc. (NASDAQ:TARA – Free Report) – Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Protara Therapeutics in a research report issued to ...

Tesla (NASDAQ:TSLA) attracted an upgrade from Cantor Fitzgerald on Wednesday after the firm visited the company's Gigafactory and AI data centers in Austin. The firm moved Tesla (NASDAQ ...

Fintel reports that on March 19, 2025, Cantor Fitzgerald upgraded their outlook for Tesla (SNSE:TSLA) from Neutral to Overweight. There are 5,232 funds or institutions reporting positions in Tesla.

The Central Bank said Cantor failed on a number of occasions to report identified suspicious transactions that may have indicated market abuse. The Central Bank of Ireland fined Cantor Fitzgerald ...

Fintel reports that on March 19, 2025, Cantor Fitzgerald upgraded their outlook for Tesla (NasdaqGS:TSLA) from Neutral to Overweight. As of March 4, 2025, the average one-year price target for ...

In a report released today, Andres Sheppard from Cantor Fitzgerald maintained a Buy rating on Ouster (OUST – Research Report), with a price target of $11.00. The company’s shares closed ...